13262-48-1

Basic information

• Product Name: biphenyl-4-ylurea
• Synonyms: biphenyl-4-ylurea;1,1'-Biphenyl-4-ylurea;N-(Biphenyl-4-yl)urea;(4-phenylphenyl)urea
• CAS NO: 13262-48-1
• Molecular Formula: C₁₃H₁₂N₂O
• Molecular Weight: 212.24718
• EINECS: 236-257-2
• Mol File: 13262-48-1.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 366.9°Cat760mmHg
• Flash Point: 175.7°C
• Appearance: /
• Density: 1.213g/cm³
• Vapor Pressure: 1.42E-05mmHg at 25°C
• Refractive Index: 1.652
• CAS DataBase Reference: biphenyl-4-ylurea(CAS DataBase Reference)
• NIST Chemistry Reference: biphenyl-4-ylurea(13262-48-1)
• EPA Substance Registry System: biphenyl-4-ylurea(13262-48-1)

Safety Data

• Hazardous Substances Data: 13262-48-1(Hazardous Substances Data)

Usage

General Description

Biphenyl-4-ylurea, also known as diphenyl-4-ylurea, is a chemical compound comprised of a urea molecule attached to a biphenyl group. It is commonly used as a building block in organic synthesis and pharmaceutical research, and has potential applications in the development of pharmaceutical drugs and agrochemicals. Biphenyl-4-ylurea is known for its diverse range of biological activities, including anti-inflammatory, anti-cancer, and antiviral properties. Its structure and functional groups make it a versatile compound for the development of new chemical compounds with potential therapeutic applications.

InChI:InChI=1/C13H12N2O/c14-13(16)15-12-8-6-11(7-9-12)10-4-2-1-3-5-10/h1-9H,(H3,14,15,16)

Upstream product

• 556-89-8 nitrourea 
• 92-67-1 4-phenylalanine 
• 590-28-3 potassium cyanate 
• 92-95-5 4-biphenyl isocyanate 
• 1189-71-5 isocyanate de chlorosulfonyle 

Downstream Products

• 95745-38-3 1,3-di([1,1'-biphenyl]-4-yl)urea 

Relevant articles and documents

Novel ATP-competitive kinesin spindle protein inhibitors

Kinesin spindle protein (KSP), an ATPase responsible for spindle pole separation during mitosis that is present only in proliferating cells, has become a novel and attractive anticancer target with potential for reduced side effects compared to currently available therapies. We report herein the discovery of the first known ATP-competitive inhibitors of KSP, which display a unique activity profile as compared to the known loop 5 (L5) allosteric KSP inhibitors that are currently under clinical evaluation. Optimization of this series led to the identification of biphenyl sulfamide 20, a potent KSP inhibitor with in vitro antiproliferative activity against human cells with either wild-type KSP (HCT116) or mutant KSP (HCT116 D 130V). In a murine xenograft model with HCT116 D130V tumors, 20 showed significant antitumor activity following intraperitoneal dosing, providing in vivo proof-of-principle of the efficacy of an ATP-competitive KSP inhibitor versus tumors that are resistant to the other known KSP inhibitors.